Gefurulimab

Gefurulimab is Alexion's attempt to keep the complement franchise commercially viable as Soliris loses exclusivity and Ultomiris faces biosimilar pressure later this decade. It's a bispecific nanobody: one arm binds complement C5, the other binds serum albumin for half-life extension, small enough and long-acting enough to inject under the skin once weekly. On 29 July 2025 AstraZeneca announced that the Phase 3 PREVAIL trial (NCT05556096) in adult AChR-antibody-positive generalized myasthenia gravis (gMG) met its primary and all secondary endpoints, with full data presented at the AANEM/MGFA scientific session in October 2025 [3][9]. A pediatric Phase 3 (NCT06607627) is recruiting in parallel [1]. The gMG market is roughly 135,000 diagnosed US patients and ~130,000 across EU4+UK, with AChR+ comprising ~76,500 in the US alone; class revenue today already exceeds several billion USD between Soliris, Ultomiris, Vyvgart, Rystiggo, and Zilbrysq [10][11]. With PREVAIL positive, the science is fully de-risked - the unresolved question is whether SC-delivered anti-C5 can earn share against argenx's Vyvgart Hytrulo and UCB's Rystiggo and Zilbrysq, which already reset patient expectations around subcutaneous convenience [6][12][13]. The commercial bar, not the science, will decide this asset's contribution to the franchise.

Novel compound, never approved in any indication. The registrational adult Phase 3 PREVAIL trial (NCT05556096, n=260 randomized 1:1 across 20 countries) read out positive on 29 July 2025: gefurulimab met the primary endpoint on MG-ADL change at week 26 and all secondary endpoints, with the safety profile consistent with prior anti-C5 experience [3][9]. AstraZeneca has stated it intends to submit to regulators but has not committed to a specific filing quarter as of the most recent available disclosures; on a typical timeline, BLA submission would be expected within ~6-12 months of the readout, with potential US approval in late 2026 or 2027. A separate pediatric Phase 3 (NCT06607627) is recruiting 12 children with AChR+ gMG, with Cmax as the primary endpoint - a PK-bridging design [1]. Phase 1 work covered prefilled syringe versus autoinjector device comparability in 175 healthy adults (NCT06208488) and PK in healthy Chinese adults (NCT06677138) [2]. There is no publicly reported dedicated Phase 2 study in gMG; the program moved from Phase 1 PK/device work directly into the Phase 3 PREVAIL trial, which is not unusual for a biologic with a fully validated target. FDA granted orphan drug designation in 2023 [9]. EU orphan designation is plausible given gMG qualifies as a rare disease in the EU but it could not be independently verified, so the EMA designation field is left unset rather than estimated.

Complement C5 is a protein in your innate immune system: when it gets activated, it triggers a chain reaction that ends with a membrane attack complex punching holes in target cells. Useful for killing bacteria. Bad when your immune system has aimed it at your own neuromuscular junction. In AChR-antibody-positive gMG, autoantibodies bind the acetylcholine receptor on muscle, and complement amplifies the damage by destroying the postsynaptic membrane. Block C5 and the membrane attack complex never assembles, so the junction can heal and signal again. Patients regain strength within weeks. This mechanism is the most clinically validated approach in gMG - eculizumab proved it in REGAIN [4], and ravulizumab confirmed it in CHAMPION-MG [5]. Mechanism risk here is essentially zero, and PREVAIL has now confirmed the mechanism extends to the bispecific nanobody format [3][9]. The novel part is the format. Gefurulimab is a bispecific nanobody, a single-domain antibody fragment originally derived from camelids. One arm binds C5; the other arm binds serum albumin, which the body recycles via the FcRn receptor. By hitching a ride on albumin, the nanobody gets a long half-life without needing an Fc domain. That enables weekly subcutaneous injection in roughly a 1-mL volume rather than monthly IV infusion.

The registrational study is PREVAIL (NCT05556096): a Phase 3 global randomized, double-blind, placebo-controlled trial in adult AChR+ gMG patients (n=260, MGFA Class II-IV at screening, randomized 1:1), with the primary endpoint a change from baseline in MG-ADL score at week 26 [3][9]. MG-ADL is the standard patient-reported functional scale in this disease; eculizumab (REGAIN), ravulizumab (CHAMPION-MG), efgartigimod (ADAPT), rozanolixizumab (MycarinG, NCT03971422), and zilucoplan (RAISE, NCT04115293) all read out on it, so cross-trial comparison is at least directionally possible [4][5][6][12][13]. Randomization was stratified by baseline severity and concomitant immunosuppression. The pediatric study (NCT06607627) is much smaller at 12 patients, and its primary endpoint is Cmax (peak drug exposure), not a clinical efficacy measure [1]. That's a PK-bridging trial, not a registrational efficacy trial; pediatric approval will rely on extrapolation from adult data plus pediatric PK and safety. The pre-launch device work (NCT06208488, n=175) compared prefilled syringe to autoinjector administration in healthy adults [2]; Alexion clearly intends to launch with a patient-friendly autoinjector, which matters competitively because argenx and UCB already have SC autoinjector form factors approved.

The model gives this drug a 26% chance of eventually being approved. That figure starts from the typical approval rate for Phase 3 drugs in this area, which is about 51%, then adjusts based on ten facts about the trial and sponsor. The estimate is helped by the trial's non-randomized design, but pulled down by smaller-than-typical enrollment, a thin or weak sponsor approval record, and limited earlier-phase results. The remaining factors fall close to average for this stage and leave the number roughly where it started.

Efficacy risk: largely resolved at week 26 - PREVAIL met its primary and all secondary endpoints with effect onset as early as week one [3][9]. The unresolved efficacy question is durability beyond 26 weeks under real-world adherence to weekly SC self-injection; trough exposure dips between doses are a structural feature of weekly SC anti-C5 versus every-8-weeks IV Ultomiris. Safety risk: All anti-C5 drugs carry a US boxed warning for meningococcal infection because terminal complement is what your body uses to kill Neisseria. Patients require meningococcal vaccination before starting and lifelong monitoring [7]. Gefurulimab inherits this; PREVAIL reported no new safety signals beyond the known class profile [3][9]. No reason to expect worse than eculizumab or ravulizumab, but no reason to expect better either. Immunogenicity risk: nanobodies are camelid-derived and humanized, but the bispecific format and absence of an Fc domain mean ADAs (anti-drug antibodies) are a real possibility over chronic dosing. Loss of efficacy at 12-24 months would be a problem the Phase 3 primary readout at 26 weeks won't fully surface; this is a label and long-term-extension question. Commercial risk: this is now the dominant concern. argenx's Vyvgart Hytrulo (SC efgartigimod) and UCB's Rystiggo (SC rozanolixizumab) and Zilbrysq (SC zilucoplan) have already broken IV anti-C5's convenience moat [6][12][13]. Even with clean efficacy, payers will ask why gefurulimab should be preferred over Ultomiris (every 8 weeks IV) or Vyvgart Hytrulo (weekly SC, different mechanism). Pricing pressure will be real. IP / lifecycle risk: gefurulimab's composition-of-matter patent expiry could not be verified from public sources in this pass. For an asset framed as a lifecycle bridge across the Ultomiris biosimilar cliff, IP runway is load-bearing; treat this as a key open diligence question rather than an assumed strength.

Confirmed positive Phase 3 changes the framing from 'watch for readout' to 'evaluate commercial trajectory.' PREVAIL reported a least-squares-mean change from baseline in MG-ADL of -4.2 for gefurulimab versus -2.6 for placebo at week 26, a treatment effect of -1.6 points (p<0.0001) [9]. For context on comparable framing (all treatment-effect-vs-placebo on MG-ADL): eculizumab in REGAIN was approximately -2 points (AChR+ subgroup, ~-4.2 vs ~-2.3 from baseline) [4]; ravulizumab in CHAMPION-MG was approximately -1.6 points [5]; efgartigimod in ADAPT was approximately -2 points in the AChR+ subgroup on continuous MG-ADL [6]. Gefurulimab's treatment effect sits at the lower end of this benchmark band, comparable to ravulizumab and modestly below eculizumab and efgartigimod. The commercial question for AstraZeneca: with effect size at parity with Ultomiris and below efgartigimod, does once-weekly SC convenience and autoinjector form factor pull enough share from Ultomiris (FY2024 ~$3.8B revenue [7]) to make this a net franchise positive? gMG is a roughly $1.5B+ class today across all approved agents, with the addressable AChR+ subpopulation around 76,500 in the US and a similar order of magnitude across EU4+UK [10][11] - meaningful, but not a blockbuster expansion lane on its own. The bispecific nanobody format is also worth tracking for the broader complement pipeline; PREVAIL's success validates SC anti-C5 as a category, which matters for paroxysmal nocturnal hemoglobinuria, atypical HUS, and neuromyelitis optica. The next investor inflection points are the BLA filing announcement and any FDA action-date disclosure on subsequent earnings calls.